NCT00509613已完成1 期
Phase 1 Dose Escalation Study With Sorafenib in Combination With Sirolimus in Patients With Solid Tumor
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
- 主要终点
- identify the recommended doses for the combination of sorafenib and sirolimus for subsequent phase II studies
研究概览
简要总结
The purpose of the trial is to identify the recommended dose of sorafenib and sirolimus for combination therapy in subsequent phase 2 trials.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with histological or cytological confirmed advanced solid tumor, which is refractory to standard therapies or for which no standard therapy exists and for which there is a rationale for the therapeutic use of a combination of sorafenib and sirolimus (especially metastic RCC, malignant melanoma, HCC, NSCLC, pancreatic cancer, hormone refractory prostate cancer).
- •Men or women of at least 18 years
- •Patients who have an ECOG status of 0 or 1
- •Patients who have a life expectancy of at least 12 weeks
- •Adequate bone marrow, liver and renal function
- •Negative pregnancy test for female patients of childbearing potential
- •Women and men enrolled into this trial must use adequate birth control measures during the course of the trial.
- •Signed informed consent
排除标准
- •History of serious cardiac disease
- •Active clinically serious bacterial, viral or fungal infections (> grade 2).
- •Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C.
- •Clinically symptomatic brain or meningeal metastasis.
- •Patients with seizure disorders requiring medication (such as steroids or antiepileptics).
- •Patients with evidence or history of bleeding diathesis.
- •Substance abuse, medical, psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results.
- •Concomitant treatment with strong CYP3A4 inductors (such as rifampicin, St. John´s Wort) or CYP3A4 inhibitors (such as ketoconazole, voriconazole, itraconazole, diltiazem, verapamil, erythromycin). Moderate or weak CYP3A4 modifiers should be used concomitantly only after careful assessment of risk-benefit ratio. Concomitant use of carbamazepine, phenobarbital, phenytoin or chronic use of dexamethasone is excluded
结局指标
主要结局
identify the recommended doses for the combination of sorafenib and sirolimus for subsequent phase II studies
次要结局
- to determine the safety profile of the combination therapy of sorafenib with sirolimus
- to determine, if possible, the Maximum Tolerated Dose (MTD) of sorafenib and sirolimus in combination therapy
- to analyze pharmacokinetic PK profiles (AUC, Cmax) during combination therapy for sorafenib and sirolimus
- to evaluate efficacy of the combination descriptively (response rate and rate of stable diseases)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid TumorsRhabdomyosarcoma and Other Soft Tissue SarcomasEwing's Sarcoma Family of TumorsOsteosarcomaBrain TumorsNeuroblastomaNCT01518413HMeany17
已完成
1 期
Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion ChemotherapyHepatocellular CarcinomaNCT00933816Kindai University37
已完成
1 期
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal CancerRecurrent Colon CancerRecurrent Rectal CancerStage III Colon CancerStage III Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00134069National Cancer Institute (NCI)48
终止
1 期
Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung CancerLung CancerNCT00543335M.D. Anderson Cancer Center10
已完成
1 期
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade GliomasAnaplastic GliomaGlioblastomaBrain TumorNCT01434602National Cancer Institute (NCI)86